[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009009119A - Metodo para tratar o prevenir la inflamacion sistemica. - Google Patents

Metodo para tratar o prevenir la inflamacion sistemica.

Info

Publication number
MX2009009119A
MX2009009119A MX2009009119A MX2009009119A MX2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A MX 2009009119 A MX2009009119 A MX 2009009119A
Authority
MX
Mexico
Prior art keywords
treating
systemic inflammation
preventing systemic
subject
preventing
Prior art date
Application number
MX2009009119A
Other languages
English (en)
Inventor
Robert J Mcmahon
Josef Neu
Udo Herz
William Michael Russell
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Publication of MX2009009119A publication Critical patent/MX2009009119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a un método nuevo para tratar o prevenir inflamación sistémica en un sujeto. El método administra al sujeto una cantidad terapéuticamente eficaz de LGG inactivado.
MX2009009119A 2007-02-28 2008-02-22 Metodo para tratar o prevenir la inflamacion sistemica. MX2009009119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
MX2009009119A true MX2009009119A (es) 2009-09-04

Family

ID=39469924

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009008875A MX2009008875A (es) 2007-02-28 2008-02-22 Producto que contiene probiotico inactivado para niños o infantes.
MX2009009119A MX2009009119A (es) 2007-02-28 2008-02-22 Metodo para tratar o prevenir la inflamacion sistemica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009008875A MX2009008875A (es) 2007-02-28 2008-02-22 Producto que contiene probiotico inactivado para niños o infantes.

Country Status (14)

Country Link
US (2) US9408818B2 (es)
EP (2) EP2124977B9 (es)
CN (3) CN101636172A (es)
AT (1) ATE544457T1 (es)
BR (2) BRPI0808052A2 (es)
CA (2) CA2676956C (es)
ES (2) ES2388198T5 (es)
HK (2) HK1136969A1 (es)
MX (2) MX2009008875A (es)
MY (2) MY151892A (es)
PL (2) PL2114423T3 (es)
RU (2) RU2468807C2 (es)
TW (2) TWI494114B (es)
WO (2) WO2008106372A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
BRPI0808052A2 (pt) * 2007-02-28 2014-06-24 Mead Johnson Nutrition Co Método para tratar ou prevenir inflamação sistêmica.
CA2707656C (en) * 2007-12-06 2018-05-22 Arla Foods Amba Probiotic bacteria and regulation of fat storage
CN102960447A (zh) * 2008-11-03 2013-03-13 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
AU2010242955B2 (en) * 2009-04-29 2016-02-04 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
MY159273A (en) * 2009-05-11 2016-12-30 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
CA2786710C (en) 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
EP2637513A2 (en) 2010-11-11 2013-09-18 Nestec S.A. Frozen confections containing probiotic micro-organisms
EP2455094A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
US9545415B2 (en) * 2012-01-06 2017-01-17 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN111676171B (zh) * 2013-08-09 2023-06-06 Ab-生物股份有限公司 用于婴儿过度啼哭的益生菌
CN105765058A (zh) * 2013-11-25 2016-07-13 雀巢产品技术援助有限公司 经热处理的乳酸双歧杆菌ncc2818制剂减轻变态反应的表现
RU2687038C1 (ru) * 2013-11-29 2019-05-06 Нестек С.А. Соответствующие возрастным потребностям питательные композиции с различным содержанием белка
PT3193901T (pt) 2014-12-23 2018-06-29 4D Pharma Res Ltd Polipéptido de pirina e modulação imunitária
EA202090948A1 (ru) 2014-12-23 2020-11-30 4Д Фарма Рисерч Лимитед Иммуномодуляция
ME03595B (me) 2015-06-15 2020-07-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2748812T3 (es) 2015-06-15 2020-03-18 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3209310T (lt) 2015-11-20 2018-04-25 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018067689A2 (pt) 2016-03-04 2019-01-08 4D Pharma Plc composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
MA48941A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
EP3804737B1 (en) 2017-06-14 2022-05-18 4D Pharma Research Limited Compositions comprising bacterial strains
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6180100B1 (en) 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
DE69819477D1 (de) 1998-06-17 2003-12-11 Nestle Sa Mobile genetische Elemente als Werkzeuge zur genetischen Modifikation von L. delbrueckii oder L. helveticus
US6399055B1 (en) 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
WO2001058465A2 (en) * 2000-02-10 2001-08-16 Gregor Reid Probiotic therapy for newborns
IL156490A0 (en) 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
KR100419132B1 (ko) 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
IL157071A0 (en) 2001-02-06 2004-02-08 Nestle Sa Endotoxine binding by lactic acid bacteria and bifidobacteria
PE20030283A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
PE20030274A1 (es) 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20050100531A1 (en) 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
CA2490016C (en) 2002-06-28 2017-08-22 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
EP1608383A1 (en) 2003-03-31 2005-12-28 Alimentary Health Limited A formulation comprising a bacterial strain
ATE491348T1 (de) 2003-06-23 2011-01-15 Nestec Sa Säuglingsnährpräparat oder folgemilch
US7125963B2 (en) 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
CA2559390A1 (en) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
US8926952B2 (en) 2005-04-08 2015-01-06 The Procter & Gamble Company Methods of use of probiotic bifidobacteria for human beauty benefits
CA2604338A1 (en) * 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
US20060233762A1 (en) 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
BRPI0808052A2 (pt) * 2007-02-28 2014-06-24 Mead Johnson Nutrition Co Método para tratar ou prevenir inflamação sistêmica.

Also Published As

Publication number Publication date
EP2114423B2 (en) 2020-01-01
PL2114423T3 (pl) 2012-10-31
EP2124977B1 (en) 2012-02-08
EP2114423A1 (en) 2009-11-11
ES2381232T3 (es) 2012-05-24
CA2679374A1 (en) 2008-09-04
EP2124977B9 (en) 2012-05-02
HK1136969A1 (en) 2010-07-16
CN101678053B (zh) 2015-12-16
MY145769A (en) 2012-04-13
TWI418355B (zh) 2013-12-11
BRPI0808145A2 (pt) 2021-03-23
US9408819B2 (en) 2016-08-09
CA2679374C (en) 2016-05-31
WO2008106373A1 (en) 2008-09-04
EP2124977A1 (en) 2009-12-02
RU2009135873A (ru) 2011-04-10
US9408818B2 (en) 2016-08-09
ES2388198T5 (es) 2020-07-14
RU2009135871A (ru) 2011-04-10
CA2676956A1 (en) 2008-09-04
BRPI0808052A2 (pt) 2014-06-24
EP2114423B1 (en) 2012-06-06
CN101678053A (zh) 2010-03-24
CN105796607A (zh) 2016-07-27
TW200900075A (en) 2009-01-01
ATE544457T1 (de) 2012-02-15
CA2676956C (en) 2017-06-13
RU2468807C2 (ru) 2012-12-10
US20080206213A1 (en) 2008-08-28
WO2008106372A1 (en) 2008-09-04
TWI494114B (zh) 2015-08-01
US20080206212A1 (en) 2008-08-28
MY151892A (en) 2014-07-14
RU2468808C2 (ru) 2012-12-10
PL2124977T3 (pl) 2012-07-31
CN101636172A (zh) 2010-01-27
HK1141729A1 (zh) 2010-11-19
MX2009008875A (es) 2009-08-28
TW200906426A (en) 2009-02-16
ES2388198T3 (es) 2012-10-10

Similar Documents

Publication Publication Date Title
MY145769A (en) Method for treating or preventing systemic inflammation
MX2010006823A (es) Metodos para el tratamiento de la gota.
MY147175A (en) Method for preventing or treating the development of respiratory allergies
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
WO2012156531A3 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
NZ596916A (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
WO2009079451A3 (en) Compositions and methods of promoting wound healing
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
UA102128C2 (en) Nalmefene hydrochloride dihydrate
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
NZ700399A (en) Boronic acid conjugates of oligonucleotide analogues
PL2099769T3 (pl) Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
NZ588213A (en) Alpha-msh analogues for treating or preventing vitiligo
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
GB0710536D0 (en) Plant extract and its therapeutic use
WO2006081371A3 (en) Combination therapy with triterpenoid compounds and proteasome inhibitors
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
WO2007100435A3 (en) Use of dha and ara in the preparation of a composition for the prevention or treatment of anemia

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights